We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Thrombocytopenia Prevalence in Acute Cancer-Associated Thrombosis Patients

By LabMedica International staff writers
Posted on 05 Oct 2022

Venous thromboembolism (VTE) is a common complication in patients with cancer, with thrombosis being the second leading cause of death among outpatients undergoing chemotherapy. More...

Thrombocytopenia is also a common complication in patients with cancer, either due to the underlying malignancy or toxicity of cancer-directed therapy.

Due to the unique risk profile of cancer patients, management of cancer-associated thrombosis (CAT) requires special considerations as compared to VTE in non-cancer patients. Clinical decision-making in patients with cancer who develop both thrombosis and thrombocytopenia is challenging as thrombocytopenia increases the risk of bleeding without conferring protection against thrombosis.

Hematologists at the Beth Israel Deaconess Medical Center (Boston MA, USA) evaluated the prevalence of thrombocytopenia among patients with acute CAT. A retrospective cohort analysis of adult cancer patients was conducted between 2010 and 2021 with CAT (acute VTE within six months after new diagnosis of malignancy). VTE included acute deep vein thrombosis (DVT), pulmonary embolism (PE), abdominal or thoracic venous thrombosis, and cerebral sinus thrombosis (CST). The lowest platelet count within two weeks of (before or after) the index VTE event was identified to assess the frequency and grade of concurrent thrombocytopenia. The overall cohort was comprised of 47% females, with mean age 65.7 ± 12.8 years.

The scientists identified 3,635 patients with CAT (79.8% solid tumors, 17.8% hematologic malignancies, and 2.4% multiple concurrent cancer diagnoses). Thrombocytopenia (defined as platelet count <100,000/µL) occurred in 22% (95% CI 21%-24%) of patients with CAT with solid tumors diagnoses and 47% (95% CI 43%-51%) of patients with CAT and hematologic malignancies. Severe thrombocytopenia (platelet count <50,000/µL) occurred in 7% (95% CI 6%-8%) of patients with solid tumors and 30% (95% CI 27%-34%) of patients with hematologic malignancies.

The authors concluded that their study highlights the high co-prevalence of thrombocytopenia and CAT. Approximately 1 in 5 patients with solid tumors and 1 in 2 patients with hematologic malignancies with a diagnosis of VTE have concurrent thrombocytopenia. These point estimates serve to better define the scope of the problem and serve as justification for additional clinical trials addressing appropriate anticoagulation for acute CAT with thrombocytopenia. The study was published on September 28, 2022 in the journal Blood Advances.

Related Links:
Beth Israel Deaconess Medical Center 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Modular Hemostasis Automation Solution
CN Track
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.